Anti-androgen therapy is the mainstay therapy for prostate cancer; therefore, we examined if the gDEC could sensitize prostate cancer cells to the anti-androgen drug enzalutamide and AR-regulated prostate-specific antigen levels (PSA). This evidence concerns the gene KLK3 and prostate carcinoma.